FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153560596> ?p ?o ?g. }

• W2153560596 endingPage "S364" @default.
• W2153560596 startingPage "S364" @default.
• W2153560596 abstract "Purpose/Objective(s)To report acute toxicities from a phase II study in high-risk prostate cancer patients treated with androgen suppression and intensity-modulated radiation therapy (IMRT) with a simultaneous integrated boost.Materials/MethodsThirty-six prostate cancer patients with clinical stage ≥T3, or initial PSA ≥20 ng/mL, or Gleason score of 8-10 entered in the study. IMRT plans were designed to deliver 60 Gy in 20 fractions of 3 Gy over 4 weeks to the prostate and base of seminal vesicle (CTV60), while simultaneously delivering 44 Gy in 20 fractions of 2.2 Gy to the pelvic lymph nodes (CTV44). All patients had daily image guidance with ultrasound and/or cone-beam. PTVs were CTVs with a 7mm margin. Whole bladder and rectum constraints were as follows: V56 Gy<25%; V48 Gy<50% for the rectum and V60 Gy<25%; V52 Gy<50% for the bladder. Acute toxicity was recorded prospectively, weekly during treatment and every 3-6 months post IMRT, using the NCI CTC version 3 scoring system.ResultsMedian age is 72 years (56-85). One 80 year-old patient interrupted treatment at 54 Gy due to medical reasons diagnosed prior to IMRT. All other patients completed IMRT without interruption, and were followed for more than 3 months. Acute genito-urinary (GU) and gastro-intestinal (GI) toxicities are summarized in the table below, and were compared to EORTC data using standard fractionation (70 Gy/35 to prostate and 45 Gy/25 to pelvis). There was no grade ≥ 4 acute toxicity. Acute toxicity did not correlate with any of the dosimetric parameters examined. Of interest, beyond a follow-up of 90 days, all acute grade 3 toxicity improved.ConclusionsPoster Viewing Abstract 2389; TableAcute toxicity rates in McGill study compared to EORTC dataGrade0123McGillGU27.8%52.8%16.7%2.7%GI47.2%36.1%16.7%0%EORTCGU25.2%43.2%24.7%6.%GI3.5%33.6%18.3%8.6% Open table in a new tab Purpose/Objective(s)To report acute toxicities from a phase II study in high-risk prostate cancer patients treated with androgen suppression and intensity-modulated radiation therapy (IMRT) with a simultaneous integrated boost. To report acute toxicities from a phase II study in high-risk prostate cancer patients treated with androgen suppression and intensity-modulated radiation therapy (IMRT) with a simultaneous integrated boost. Materials/MethodsThirty-six prostate cancer patients with clinical stage ≥T3, or initial PSA ≥20 ng/mL, or Gleason score of 8-10 entered in the study. IMRT plans were designed to deliver 60 Gy in 20 fractions of 3 Gy over 4 weeks to the prostate and base of seminal vesicle (CTV60), while simultaneously delivering 44 Gy in 20 fractions of 2.2 Gy to the pelvic lymph nodes (CTV44). All patients had daily image guidance with ultrasound and/or cone-beam. PTVs were CTVs with a 7mm margin. Whole bladder and rectum constraints were as follows: V56 Gy<25%; V48 Gy<50% for the rectum and V60 Gy<25%; V52 Gy<50% for the bladder. Acute toxicity was recorded prospectively, weekly during treatment and every 3-6 months post IMRT, using the NCI CTC version 3 scoring system. Thirty-six prostate cancer patients with clinical stage ≥T3, or initial PSA ≥20 ng/mL, or Gleason score of 8-10 entered in the study. IMRT plans were designed to deliver 60 Gy in 20 fractions of 3 Gy over 4 weeks to the prostate and base of seminal vesicle (CTV60), while simultaneously delivering 44 Gy in 20 fractions of 2.2 Gy to the pelvic lymph nodes (CTV44). All patients had daily image guidance with ultrasound and/or cone-beam. PTVs were CTVs with a 7mm margin. Whole bladder and rectum constraints were as follows: V56 Gy<25%; V48 Gy<50% for the rectum and V60 Gy<25%; V52 Gy<50% for the bladder. Acute toxicity was recorded prospectively, weekly during treatment and every 3-6 months post IMRT, using the NCI CTC version 3 scoring system. ResultsMedian age is 72 years (56-85). One 80 year-old patient interrupted treatment at 54 Gy due to medical reasons diagnosed prior to IMRT. All other patients completed IMRT without interruption, and were followed for more than 3 months. Acute genito-urinary (GU) and gastro-intestinal (GI) toxicities are summarized in the table below, and were compared to EORTC data using standard fractionation (70 Gy/35 to prostate and 45 Gy/25 to pelvis). There was no grade ≥ 4 acute toxicity. Acute toxicity did not correlate with any of the dosimetric parameters examined. Of interest, beyond a follow-up of 90 days, all acute grade 3 toxicity improved. Median age is 72 years (56-85). One 80 year-old patient interrupted treatment at 54 Gy due to medical reasons diagnosed prior to IMRT. All other patients completed IMRT without interruption, and were followed for more than 3 months. Acute genito-urinary (GU) and gastro-intestinal (GI) toxicities are summarized in the table below, and were compared to EORTC data using standard fractionation (70 Gy/35 to prostate and 45 Gy/25 to pelvis). There was no grade ≥ 4 acute toxicity. Acute toxicity did not correlate with any of the dosimetric parameters examined. Of interest, beyond a follow-up of 90 days, all acute grade 3 toxicity improved. ConclusionsPoster Viewing Abstract 2389; TableAcute toxicity rates in McGill study compared to EORTC dataGrade0123McGillGU27.8%52.8%16.7%2.7%GI47.2%36.1%16.7%0%EORTCGU25.2%43.2%24.7%6.%GI3.5%33.6%18.3%8.6% Open table in a new tab" @default.
• W2153560596 created "2016-06-24" @default.
• W2153560596 creator A5023265387 @default.
• W2153560596 creator A5024741202 @default.
• W2153560596 creator A5044903935 @default.
• W2153560596 creator A5048415613 @default.
• W2153560596 creator A5051752063 @default.
• W2153560596 creator A5078274025 @default.
• W2153560596 creator A5091337701 @default.
• W2153560596 date "2012-11-01" @default.
• W2153560596 modified "2023-09-27" @default.
• W2153560596 title "Hypofractionated IMRT With Simultaneous Integrated Boost for High-risk Prostate Cancer Patients: Acute Toxicity Report" @default.
• W2153560596 doi "https://doi.org/10.1016/j.ijrobp.2012.07.961" @default.
• W2153560596 hasPublicationYear "2012" @default.
• W2153560596 type Work @default.
• W2153560596 sameAs 2153560596 @default.
• W2153560596 citedByCount "0" @default.
• W2153560596 crossrefType "journal-article" @default.
• W2153560596 hasAuthorship W2153560596A5023265387 @default.
• W2153560596 hasAuthorship W2153560596A5024741202 @default.
• W2153560596 hasAuthorship W2153560596A5044903935 @default.
• W2153560596 hasAuthorship W2153560596A5048415613 @default.
• W2153560596 hasAuthorship W2153560596A5051752063 @default.
• W2153560596 hasAuthorship W2153560596A5078274025 @default.
• W2153560596 hasAuthorship W2153560596A5091337701 @default.
• W2153560596 hasBestOaLocation W21535605961 @default.
• W2153560596 hasConcept C116263406 @default.
• W2153560596 hasConcept C121608353 @default.
• W2153560596 hasConcept C126322002 @default.
• W2153560596 hasConcept C126838900 @default.
• W2153560596 hasConcept C126894567 @default.
• W2153560596 hasConcept C141071460 @default.
• W2153560596 hasConcept C2776235491 @default.
• W2153560596 hasConcept C2778357063 @default.
• W2153560596 hasConcept C2780192828 @default.
• W2153560596 hasConcept C2781074409 @default.
• W2153560596 hasConcept C29730261 @default.
• W2153560596 hasConcept C2989005 @default.
• W2153560596 hasConcept C509974204 @default.
• W2153560596 hasConcept C71924100 @default.
• W2153560596 hasConceptScore W2153560596C116263406 @default.
• W2153560596 hasConceptScore W2153560596C121608353 @default.
• W2153560596 hasConceptScore W2153560596C126322002 @default.
• W2153560596 hasConceptScore W2153560596C126838900 @default.
• W2153560596 hasConceptScore W2153560596C126894567 @default.
• W2153560596 hasConceptScore W2153560596C141071460 @default.
• W2153560596 hasConceptScore W2153560596C2776235491 @default.
• W2153560596 hasConceptScore W2153560596C2778357063 @default.
• W2153560596 hasConceptScore W2153560596C2780192828 @default.
• W2153560596 hasConceptScore W2153560596C2781074409 @default.
• W2153560596 hasConceptScore W2153560596C29730261 @default.
• W2153560596 hasConceptScore W2153560596C2989005 @default.
• W2153560596 hasConceptScore W2153560596C509974204 @default.
• W2153560596 hasConceptScore W2153560596C71924100 @default.
• W2153560596 hasIssue "3" @default.
• W2153560596 hasLocation W21535605961 @default.
• W2153560596 hasOpenAccess W2153560596 @default.
• W2153560596 hasPrimaryLocation W21535605961 @default.
• W2153560596 hasRelatedWork W1544952821 @default.
• W2153560596 hasRelatedWork W1980245127 @default.
• W2153560596 hasRelatedWork W2002769163 @default.
• W2153560596 hasRelatedWork W2055660589 @default.
• W2153560596 hasRelatedWork W2092577047 @default.
• W2153560596 hasRelatedWork W2114214906 @default.
• W2153560596 hasRelatedWork W2127440557 @default.
• W2153560596 hasRelatedWork W2288665527 @default.
• W2153560596 hasRelatedWork W3080295203 @default.
• W2153560596 hasRelatedWork W3168348566 @default.
• W2153560596 hasVolume "84" @default.
• W2153560596 isParatext "false" @default.
• W2153560596 isRetracted "false" @default.
• W2153560596 magId "2153560596" @default.
• W2153560596 workType "article" @default.